HWP
SRPT icon

Highline Wealth Partners’s Sarepta Therapeutics SRPT Stock Holding History

Highline Wealth Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.28K Buy
+127
New +$2.4K ﹤0.01% 1154
2025
Q2 		– Sell
-2
Closed -$128 – 1061
2025
Q1 		$128 Buy
+2
New +$211 ﹤0.01% 982

Other funds holding SRPT

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
GIC
Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Highline Wealth Partners's SRPT Position: Q2 2026 in Review

Highline Wealth Partners opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 127 shares worth $2.28K. The stake represents ﹤0.01% of the portfolio and ranks #1154 among its holdings. This is a return to the name: Highline Wealth Partners previously reported a position in SRPT as recently as Q1 2025.

Highline Wealth Partners first reported a position in SRPT in Q1 2025 and has held it in 2 quarters since. 33 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Highline Wealth Partners held 127 shares of Sarepta Therapeutics worth $2.28K as of Q2 2026.
  • Sarepta Therapeutics was a new Highline Wealth Partners position in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Highline Wealth Partners's portfolio in Q2 2026, its #1154 holding.
  • Highline Wealth Partners first reported a position in Sarepta Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 33 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Highline Wealth Partners's 13F filing for Q2 2026, filed 15 Jul 2026.